No abstract available.
Inflammatory Bowel Diseases* ; Leukocyte L1 Antigen Complex*

No abstract available.
Inflammatory Bowel Diseases* ; Leukocyte L1 Antigen Complex*

No abstract available.
Intestinal Diseases* ; Leukocyte L1 Antigen Complex*

No abstract available.
Colitis, Ulcerative* ; Humans ; Leukocyte L1 Antigen Complex* ; Ulcer*

No abstract available.
Humans ; Inflammatory Bowel Diseases* ; Leukocyte L1 Antigen Complex*

No abstract available.
Humans ; Inflammatory Bowel Diseases* ; Korea* ; Leukocyte L1 Antigen Complex*

No abstract available.
Constipation/*diagnosis ; Female ; Hirschsprung Disease/*diagnosis ; Humans ; Leukocyte L1 Antigen Complex/*analysis ; Male

BACKGROUND/AIMS: This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD). METHODS: Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8-26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored. RESULTS: Mean adalimumab serum concentrations during the induction phase were 13.9-18.1 µg/mL (160/80 mg group) and 7.5-9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups. CONCLUSIONS: Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported.
Adult ; Asian Continental Ancestry Group* ; Crohn Disease* ; Humans ; Leukocyte L1 Antigen Complex ; Pharmacokinetics

<b>OBJECTIVESb>To study the essence of N-terminal amino acid sequence of 12 000-protein in gingival crevicular fluid (GCF).

<b>METHODSb>GCF samples from patients with RPP and AP were collected. 12 000-protein was separated by SDS-PAGE and transformed to PVDF by electronic transformation. The aim band was cut to be analyzed in 491 Protein Sequencer.

<b>RESULTSb>The first ten of N-terminal amino acid sequence of 12 000-protein in GCF was Met, Leu, Thr, Glu, Leu, Glu, Lys, Ala, Leu, Asn. Through checking up in MS-Edman, the sequence was similar to "Ca binding protein, MRP8" which is the light subunit of Calprotectin.

<b>CONCLUSIONSb>Calprotectin is a major protein in granulocytes and monocytes, and is related to many inflammatory diseases, maybe served as a effective marker for evaluating the inflammation of periodontium.

OBJECTIVE: Calprotectin, the heterdimer of S100A8 and S100A9, is the major cytoplasmic protein of neutrophils, which is also expressed or induced in gingival epithelial cells, activated mononuclear macrophages and vascular endothelial cells. Calprotectin is intimately associated with the initiation and progression of periodontitis, but the in vivo expression patterns of calprotectin in healthy and inflamed periodontal tissue are not fully understood. To observe the expression, distribution and cellular localization of calprotectin in the samples of healthy periodontal tissues and experimental periodontitis tissues of Beagles and to explore their relationship with periodontal inflammation and possible effect. METHODS: Experimental periodontitis model was established by ligation around the mandibular second molar of the Beagle dogs, while the contralateral teeth were healthy controls. Induction duration was 12 weeks, before the dogs were executed. Tissue specimens were demineralized and serial sections were made conventionally. The in vivo expression of calprotectin in the healthy and inflamed periodontal tissues were examined by immunohistochemistry. The in vitro expression of calprotectin in human primary gingival fibroblasts (GFs) and periodontal ligament (PDL) cells were detected by immunocytochemistry. RESULTS: Immunohistochemistry analysis indicated that calprotectin was expressed in gingival epithelial cells and infiltrated neutrophils in the healthy periodontium within the gingival epithelium, S100A8/A9 was most strongly expressed in the junctional epithelium, followed by surface epithelium, and least expressed in the sulcular epithelium. The S100A8/A9 expression levels were sharply defined at the junction between the junctional epithelium and the sulcular epithelium. In periodontal inflammatory lesions, the expression level of calprotectin in sulcular epithelium and junctional epithelium was up-regulated than that in the healthy gingival epithelium. Calprotectin was inducibly expressed in fibroblast-like cells in gingival connective tissue and periodontal ligament tissue, microvascular endothelial cells (ECs) and bone marrow fibroblasts under inflammatory conditions. Additionally, the expression of calprotectin in primary human GFs and PDL cells was confirmed by immunnocytochemistry staining. CONCLUSION Constitutively expressed in neutrophils and gingival epithelial cells, and calprotectin might maintain the homeostasis and integrity of periodontium. Inflammation-induced expression of calprotectin in GFs, PDL cells, microvascular ECs and bone marrow fibroblasts might process anti-microbial function and promote leukocytes transmigration to defend the host against the microorganisms.
Animals ; Dogs ; Endothelial Cells ; Epithelial Attachment ; Gingiva ; Humans ; Leukocyte L1 Antigen Complex ; Periodontium